Resources

UK biotech financing hit a five-year high in the second quarter of 2026, with total equity financing reaching £2.11 billion, including a record £2.05 billion in venture capital.

The UK’s innovative life sciences sector has called on Government to deliver policy continuity, unlock scale-up investment and improve patient access to new medicines.

BIA calls for coordinated action and a clear mandate for Health Data Research Service (HDRS) to prioritise UK value creation with health innovators and job creators, a key sector for economic growth

UK biotech financing showed signs of recovery in the first quarter of 2026, driven by a rebound in venture capital investment.

The UK’s biosolutions sector has established itself as a billion-pound frontier industry, with companies raising £1.46 billion in equity investment since 2018.

Charlotte Cane, MP for Ely and East Cambridgeshire, visited local life science companies on 31 March to see for herself how new medicines and medical technologies are being developed.

Despite a marginal positive shift at CEO level, overall representation of women in leadership positions have stalled across the UK biotech sector.

The BioIndustry Association (BIA) has recognised the achievements of Dr Ruth McKernan CBE, neuroscientist, entrepreneur, investor and former Chair of the BIA Board, with the inaugural Chiswell Lifetime Achievement Award.

UK biotech has demonstrated resilience in a challenging 2025 and enters 2026 with renewed confidence and broadening investor appetite, the BioIndustry Association’s (BIA) report UK biotech financing 2025 has found.

We are delighted to announce the appointment of Professor Chris Molloy as our new Chief Executive Officer, starting in May 2026.

Our latest report demonstrates the real-world success and scalable manufacturing available in the UK’s globally competitive ecosystem.

The BioIndustry Association (BIA) released From Innovation to Impact: Unlocking Patient Access to Innovative Rare Disease Medicines, calling for new pathway to give UK patients access to innovative rare disease medicines.

More than 110,000 people in the UK live with a muscle-wasting condition which gradually damages the way their muscles work. Over time, it stops them from living everyday life. In some cases, lives will be cut short. Through this partnership, the BIA will leverage the network it has fostered in the UK life sciences and biotech sector to support those affected by muscle-wasting conditions.

Cath Green OBE received the Peter Dunnill Award for her exceptional leadership during COVID-19; the Future Targeted Healthcare Manufacturing Hub was awarded the Richard Wilson Impact Award and Emilia Reyes Pabon received the Bioprocessing Apprentice of the Year Award.

New BIA data shows venture capital activity slowing amid the longest global funding drought in the sector. Despite a landmark M&A deal validating UK science, the figures signal a fragile moment that needs urgent government action.

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

BIA and Japan Bioindustry Association signed an MOU, agreeing to work together to connect the two countries’ life sciences and biotech ecosystems to accelerate medical innovation and the commercialisation of engineering biology.

Shaun Grady will be the new Chair of BIA, effective from January 2026. He succeeds Dr Daniel Mahony, who has served as BIA Chair since January 2022 and has played a pivotal role in steering the association.

The BioIndustry Association today publishes new data revealing that the UK’s life sciences sector attracted £1.23 billion in venture capital (VC) investment in the first half of 2025, thereby putting it on track to match or surpass 2024’s total.

Responding to the Life Sciences Sector Plan, BIA Chair Dr Daniel Mahony said the following.